FAQ/Help |
Calendar |
Search |
Today's Posts |
03-14-2019, 02:06 PM | #3 | ||
|
|||
Member
|
This was just pharmacokinetics and biomarker data analysis. We’re all still waiting for primary and secondary objective results which would give indications about efficacy. Some of the reported results in this article were very strange.
|
||
Reply With Quote |
|
|
Similar Threads | ||||
Thread | Forum | |||
Recruitment has begun for the Georgetown University "PD Nilotinib" phase 2 trial | Parkinson's Disease | |||
Georgetown Clinical Trial of Nilotinib in Alzheimer’s Disease Begins | Parkinson's Disease | |||
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parki | Parkinson's Disease | |||
Georgetown Receives FDA Clearance for Trial with Nilotinib in Alzheim | Parkinson's Disease | |||
Six month follow up on Nilotinib trial. | Parkinson's Disease |